Long-term survival patients had higher proportion of CA19-9 low-secretion (CA19-9 normal) than that of patients with non long-term survival. The prognosis of CA19-9-Low&Lewis (−) patients was worse than that of CA19-9-Low&Lewis (+). For the CA19-9-Low&Lewis (+) subgroup, chemotherapy plus radiotherapy but not chemotherapy was found to be an independent prognostic factor.